Madhav Thambisetty

List of Publications by Year
in descending order

100 papers	8,504 citations	61687 45 h-index	58552 86 g-index
112 all docs	112 docs citations	112 times ranked	13513 citing authors

#	Article	IF	Citations
1	Comparative Risk of Alzheimer Disease and Related Dementia Among Medicare Beneficiaries With Rheumatoid Arthritis Treated With Targeted Disease-Modifying Antirheumatic Agents. JAMA Network Open, 2022, 5, e226567.	2.8	16
2	Mitochondrial respiratory chain protein co-regulation in the human brain. Heliyon, 2022, 8, e09353.	1.4	4
3	Bile acid synthesis, modulation, and dementia: A metabolomic, transcriptomic, and pharmacoepidemiologic study. PLoS Medicine, 2021, 18, e1003615.	3.9	38
4	A multicentre validation study of the diagnostic value of plasma neurofilament light. Nature Communications, 2021, 12, 3400.	5.8	219
5	Acid ceramidase promotes senescent cell survival. Aging, 2021, 13, 15750-15769.	1.4	11
6	Abnormal brain cholesterol homeostasis in Alzheimer's disease—a targeted metabolomic and transcriptomic study. Npj Aging and Mechanisms of Disease, 2021, 7, 11.	4.5	59
7	Systematic Identification of circRNAs in Alzheimer's Disease. Genes, 2021, 12, 1258.	1.0	9
8	Alzheimer's drugs: Does reducing amyloid work?. Science, 2021, 374, 544-545.	6.0	14
9	A brain proteomic signature of incipient Alzheimer's disease in young *APOE* ε4 carriers identifies novel drug targets. Science Advances, 2021, 7, eabi8178.	4.7	23
10	Multimodal Imaging and Visual Evoked Potentials Reveal Key Structural and Functional Features That Distinguish Symptomatic From Presymptomatic Huntington's Disease Brain. Neurology India, 2021, 69, 1247-1258.	0.2	4
11	Targeting abnormal metabolism in Alzheimer's disease: The Drug Repurposing for Effective Alzheimer's Medicines (DREAM) study. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2020, 6, e12095.	1.8	10
12	Plasma Apolipoprotein E Levels and Risk of Dementia—You Are the Company You Keep. JAMA Network Open, 2020, 3, e209501.	2.8	1
13	Shared proteomic effects of cerebral atherosclerosis and Alzheimer's disease on the human brain. Nature Neuroscience, 2020, 23, 696-700.	7.1	86
14	Interaction between Apolipoprotein E and Butyrylcholinesterase Genes on Risk of Alzheimer's Disease in a Prospective Cohort Study. Journal of Alzheimer's Disease, 2020, 75, 417-427.	1.2	2
15	Plasma proteomic signatures predict dementia and cognitive impairment. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2020, 6, e12018.	1.8	20
16	Blood Metabolite Signatures of Metabolic Syndrome in Two Cross-Cultural Older Adult Cohorts. International Journal of Molecular Sciences, 2020, 21, 1324.	1.8	15
17	Dysregulation of multiple metabolic networks related to brain transmethylation and polyamine pathways in Alzheimer disease: A targeted metabolomic and transcriptomic study. PLoS Medicine, 2020, 17, e1003012.	3.9	90
18	Large-scale proteomic analysis of Alzheimer's disease brain and cerebrospinal fluid reveals early changes in energy metabolism associated with microglia and astrocyte activation. Nature Medicine, 2020, 26, 769-780.	15.2	547

#	Article	IF	Citations
19	Biological sex and DNA repair deficiency drive Alzheimer's disease via systemic metabolic remodeling and brain mitochondrial dysfunction. Acta Neuropathologica, 2020, 140, 25-47.	3.9	45
20	Blood Metabolite Signature of Metabolic Syndrome Implicates Alterations in Amino Acid Metabolism: Findings from the Baltimore Longitudinal Study of Aging (BLSA) and the Tsuruoka Metabolomics Cohort Study (TMCS). International Journal of Molecular Sciences, 2020, 21, 1249.	1.8	19
21	Sex differences in the genetic predictors of Alzheimer's pathology. Brain, 2019, 142, 2581-2589.	3.7	65
22	Individualized clinical management of patients at risk for Alzheimer's dementia. Alzheimer's and Dementia, 2019, 15, 1588-1602.	0.4	49
23	Bimanual Gesture Imitation Links to Cognition and Olfaction. Journal of the American Geriatrics Society, 2019, 67, 2581-2586.	1.3	6
24	Neurotransmitter Imbalance in the Brain and Alzheimer's Disease Pathology. Journal of Alzheimer's Disease, 2019, 72, 35-43.	1.2	42
25	Large-scale proteomic analysis of human brain identifies proteins associated with cognitive trajectory in advanced age. Nature Communications, 2019, 10, 1619.	5.8	144
26	Obesity and Longer Term Risks of Dementia in 65–74 Year Olds. Age and Ageing, 2019, 48, 367-373.	0.7	24
27	Neuropathologic, genetic, and longitudinal cognitive profiles in primary age-related tauopathy (PART) and Alzheimer's disease. Alzheimer's and Dementia, 2019, 15, 8-16.	0.4	83
28	α2-macroglobulin in Alzheimer's disease: new roles for an old chaperone. Biomarkers in Medicine, 2018, 12, 311-314.	0.6	11
29	Characterization of 3 Novel Tau Radiopharmaceuticals, ^{11}C-RO-963, ^{11}C-RO-643, and ^{18}F-RO-948, in Healthy Controls and in Alzheimer Subjects. Journal of Nuclear Medicine, 2018, 59, 1869-1876.	2.8	81
30	Evidence for brain glucose dysregulation in Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 318-329.	0.4	320
31	A Decade of Blood Biomarkers for Alzheimer's Disease Research: An Evolving Field, Improving Study Designs, and the Challenge of Replication. Journal of Alzheimer's Disease, 2018, 62, 1181-1198.	1.2	80
32	Deep proteomic network analysis of Alzheimer's disease brain reveals alterations in RNA binding proteins and RNA splicing associated with disease. Molecular Neurodegeneration, 2018, 13, 52.	4.4	178
33	Sex-specific genetic predictors of Alzheimer's disease biomarkers. Acta Neuropathologica, 2018, 136, 857-872.	3.9	87
34	Sex-Specific Association of Apolipoprotein E With Cerebrospinal Fluid Levels of Tau. JAMA Neurology, 2018, 75, 989.	4.5	223
35	Brain and blood metabolite signatures of pathology and progression in Alzheimer disease: A targeted metabolomics study. PLoS Medicine, 2018, 15, e1002482.	3.9	336
36	Prevalence of dementia subtypes in United States Medicare fee-for-service beneficiaries, 2011–2013. Alzheimer's and Dementia, 2017, 13, 28-37.	0.4	218

#	Article	IF	Citations
37	Dysregulation of lipids in Alzheimer's disease and their role as potential biomarkers. Alzheimer's and Dementia, 2017, 13, 810-827.	0.4	146
38	Understanding mechanisms and seeking cures for Alzheimer's disease: why we must be â€œextraordinarily diverseâ€ American Journal of Physiology - Cell Physiology, 2017, 313, C353-C361.	2.1	7
39	Peril beyond the winner's curse: A small sample size is the bane of biomarker discovery. Alzheimer's and Dementia, 2017, 13, 606-607.	0.4	3
40	Metabolic network failures in Alzheimer's disease: A biochemical roadÂmap. Alzheimer's and Dementia, 2017, 13, 965-984.	0.4	362
41	Association between Plasma Ceramides and Phosphatidylcholines and Hippocampal Brain Volume in Late Onset Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2017, 60, 809-817.	1.2	72
42	A Multi-network Approach Identifies Protein-Specific Co-expression in Asymptomatic and Symptomatic Alzheimerâ€™s Disease. Cell Systems, 2017, 4, 60-72.e4.	2.9	381
43	Personality Change in the Preclinical Phase of Alzheimer Disease. JAMA Psychiatry, 2017, 74, 1259.	6.0	94
44	Midlife anticholinergic drug use, risk of Alzheimer's disease, and brain atrophy in communityâ€dwelling older adults. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2017, 3, 471-479.	1.8	45
45	SPARCL1 Accelerates Symptom Onset in Alzheimerâ€™s Disease and Influences Brain Structure and Function During Aging. Journal of Alzheimer's Disease, 2017, 61, 401-414.	1.2	21
46	Sex-Dependent Associations of Serum Uric Acid with Brain Function During Aging. Journal of Alzheimer's Disease, 2017, 60, 699-706.	1.2	14
47	[P3â€“207]: THE ENDOPHENOTYPE ASSOCIATION SCORE IN EARLY ALZHEIMER's DISEASE (EASEâ€AD): DISCOVERING NOVEL BLOOD AND BRAIN METABOLITE SIGNATURES OF PATHOLOGY AND PROGRESSION. Alzheimer's and Dementia, 2017, 13, P1015.	0.4	0
48	[P3â€“166]: NEUROTRANSMITTERâ€SPECIFIC METABOLISM IS RELATED TO SEVERITY OF PATHOLOGY AND SYMPTOM EXPRESSION IN ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P997.	0.4	0
49	[ICâ€Pâ€188]: ON EVALUATION OF TAU ACCUMULATIONS IN LONGITUDINAL STUDIES OF ALZHEIMER's DISEASE (AD): IMPLICATIONS FROM A PET STUDY WITH [18F]RO6958948. Alzheimer's and Dementia, 2017, 13, P139.	0.4	5
50	Association between fatty acid metabolism in the brain and Alzheimer disease neuropathology and cognitive performance: A nontargeted metabolomic study. PLoS Medicine, 2017, 14, e1002266.	3.9	215
51	Rhoâ€associated protein kinase 1 (<scp>ROCK</scp>1) is increased in Alzheimer's disease and <scp>ROCK</scp>1 depletion reduces amyloidâ€Î² levels in brain. Journal of Neurochemistry, 2016, 138, 525-531.	2.1	97
52	Blood-Based Biomarker Candidates of Cerebral Amyloid Using PiB PET in Non-Demented Elderly. Journal of Alzheimer's Disease, 2016, 52, 561-572.	1.2	41
53	F1â€02â€04: Plasma Phosphatidylcholines are Associated with Alzheimer's Disease as Well as Brain Function and Cognitive Performance During Aging. Alzheimer's and Dementia, 2016, 12, P165.	0.4	0
54	P2â€106: Brain and Blood Metabolite Signatures of Pathology and Progression in Alzheimerâ€™s Disease. Alzheimer's and Dementia, 2016, 12, P652.	0.4	0

#	Article	IF	Citations
55	Blood glucose levels and cortical thinning in cognitively normal, middle-aged adults. Journal of the Neurological Sciences, 2016, 365, 89-95.	0.3	22
56	Changes in the detergent-insoluble brain proteome linked to amyloid and tau in Alzheimer's Disease progression. Proteomics, 2016, 16, 3042-3053.	1.3	69
57	Plasma apolipoprotein J as a potential biomarker for Alzheimer's disease: Australian Imaging, Biomarkers and Lifestyle study of aging. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2016, 3, 18-26.	1.2	30
58	Blood metabolite markers of preclinical Alzheimer's disease in two longitudinally followed cohorts of older individuals. Alzheimer's and Dementia, 2016, 12, 815-822.	0.4	138
59	Blood metabolite markers of cognitive performance and brain function in aging. Journal of Cerebral Blood Flow and Metabolism, 2016, 36, 1212-1223.	2.4	53
60	State- and trait-dependent associations of vitamin-D with brain function during aging. Neurobiology of Aging, 2016, 39, 38-45.	1.5	26
61	P4-187: Midlife adiposity predicts earlier onset of Alzheimer's dementia, neuropathology, and presymptomatic cerebral amyloid accumulation. , 2015, 11, P851-P852.		1
62	P4â€185: First inâ€human PET study of 3 novel tau radiopharmaceuticals: [^{11}C]RO6924963, [^{11}C]RO6931643, and [^{18}F]RO6958948. Alzheimer's and Dementia, 2015, 11, P850.	0.4	12
63	Metabolomic Method: UPLC-q-ToF Polar and Non-Polar Metabolites in the Healthy Rat Cerebellum Using an In-Vial Dual Extraction. PLoS ONE, 2015, 10, e0122883.	1.1	20
64	Changes in AÎ² biomarkers and associations with APOE genotype in 2Âlongitudinal cohorts. Neurobiology of Aging, 2015, 36, 2333-2339.	1.5	60
65	O2-13-01: Predictive blood metabolite markers of preclinical Alzheimer's disease in the baltimore longitudinal study of aging. , 2015, 11, P204-P205.		0
66	A Subset of Cerebrospinal Fluid Proteins from a Multi-Analyte Panel Associated with Brain Atrophy, Disease Classification and Prediction in Alzheimerâ€™s Disease. PLoS ONE, 2015, 10, e0134368.	1.1	26
67	Aggregation Properties of the Small Nuclear Ribonucleoprotein U1-70K in Alzheimer Disease. Journal of Biological Chemistry, 2014, 289, 35296-35313.	1.6	42
68	THE ENTORHINAL CORTEX-HIPPOCAMPAL SYSTEM IS AN EARLY TARGET OF CLUSTERIN-RELATED NEURODEGENERATION IN ALZEIMER'S DISEASE. , 2014, 10, P160-P160.		0
69	Soluble Interleukinâ€6 Receptor Levels and Risk of Dementia: One More Signpost on a Long Road Ahead. Journal of the American Geriatrics Society, 2014, 62, 772-774.	1.3	4
70	Evidence of altered phosphatidylcholine metabolism in Alzheimer's disease. Neurobiology of Aging, 2014, 35, 271-278.	1.5	256
71	Interleukin-6 is linked to longitudinal rates of cortical thinning in aging. Translational Neuroscience, 2014, 5, 1-7.	0.7	31
72	Alzheimer Risk Variant CLU and Brain Function During Aging. Biological Psychiatry, 2013, 73, 399-405.	0.7	62

#	Article	IF	Citations
73	Pharmacologic Inhibition of ROCK2 Suppresses Amyloid-β Production in an Alzheimer's Disease Mouse Model. Journal of Neuroscience, 2013, 33, 19086-19098.	1.7	118
74	Alzheimer's disease risk genes and the age-at-onset phenotype. Neurobiology of Aging, 2013, 34, 2696.e1-2696.e5.	1.5	27
75	Impaired glucose tolerance in midlife and longitudinal changes in brain function during aging. Neurobiology of Aging, 2013, 34, 2271-2276.	1.5	42
76	Effect of Complement CR1 on Brain Amyloid Burden During Aging and Its Modification by APOE Genotype. Biological Psychiatry, 2013, 73, 422-428.	0.7	75
77	Glucose Intolerance, Insulin Resistance, and Pathological Features of Alzheimer Disease in the Baltimore Longitudinal Study of Aging. JAMA Neurology, 2013, 70, 1167.	4.5	130
78	Abnormal Gephyrin Immunoreactivity Associated With Alzheimer Disease Pathologic Changes. Journal of Neuropathology and Experimental Neurology, 2013, 72, 1009-1015.	0.9	29
79	The Utility of ^{11}C-Arachidonate PET to Study *in vivo* Dopaminergic Neurotransmission in Humans. Journal of Cerebral Blood Flow and Metabolism, 2012, 32, 676-684.	2.4	20
80	Baseline Cardiovascular Risk Predicts Subsequent Changes in Resting Brain Function. Stroke, 2012, 43, 1542-1547.	1.0	39
81	Plasma Biomarkers Associated With the Apolipoprotein E Genotype and Alzheimer Disease. Archives of Neurology, 2012, 69, 1310.	4.9	186
82	Processing and memory for emotional and neutral material in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2012, 13, 592-598.	2.3	10
83	Plasma clusterin concentration is associated with longitudinal brain atrophy in mild cognitive impairment. NeuroImage, 2012, 59, 212-217.	2.1	123
84	Plasma Based Markers of [11C] PiB-PET Brain Amyloid Burden. PLoS ONE, 2012, 7, e44260.	1.1	89
85	Plasma Biomarkers of Brain Atrophy in Alzheimer's Disease. PLoS ONE, 2011, 6, e28527.	1.1	106
86	Proteome-Based Plasma Markers of Brain Amyloid-β Deposition in Non-Demented Older Individuals. Journal of Alzheimer's Disease, 2011, 22, 1099-1109.	1.2	69
87	APOE ε4 Genotype and Longitudinal Changes in Cerebral Blood Flow in Normal Aging. Archives of Neurology, 2010, 67, 93-8.	4.9	166
88	Association of Plasma Clusterin Concentration With Severity, Pathology, and Progression in Alzheimer Disease. Archives of General Psychiatry, 2010, 67, 739.	13.8	353
89	Blood-based biomarkers of Alzheimer's disease: challenging but feasible. Biomarkers in Medicine, 2010, 4, 65-79.	0.6	162
90	Longitudinal changes in cortical thickness associated with normal aging. NeuroImage, 2010, 52, 1215-1223.	2.1	287

#	Article	IF	Citations
91	O2-05-01: Clusterin, an amyloid chaperone protein in plasma is associated with longitudinal brain atrophy in mild cognitive impairment. , 2010, 6, S106-S107.		0
92	Do extracellular chaperone proteins in plasma have potential as Alzheimerâ€™s disease biomarkers?. Biomarkers in Medicine, 2010, 4, 831-834.	0.6	9
93	A proposed metabolic strategy for monitoring disease progression in Alzheimer's disease. Electrophoresis, 2009, 30, 1235-1239.	1.3	82
94	Proteome-based identification of plasma proteins associated with hippocampal metabolism in early Alzheimerâ€™s disease. Journal of Neurology, 2008, 255, 1712-1720.	1.8	78
95	Utility of the Malayalam translation of the 7- minute screen for <i>Alzheimer's disease</i> risk in an Indian community. Neurology India, 2008, 56, 161.	0.2	7
96	A Genetic Risk Factor for Periodic Limb Movements in Sleep. New England Journal of Medicine, 2007, 357, 639-647.	13.9	582
97	Proteomics of Alzheimerâ€™s disease: understanding mechanisms and seeking biomarkers. Expert Review of Proteomics, 2007, 4, 227-238.	1.3	43
98	Diagnosis and management of MELAS. Expert Review of Molecular Diagnostics, 2004, 4, 631-644.	1.5	50
99	Hypertensive brainstem encephalopathy: clinical and radiographic features. Journal of the Neurological Sciences, 2003, 208, 93-99.	0.3	51
100	A Practical Approach to the Diagnosis and Management of MELAS: Case Report and Review. Neurologist, 2002, 8, 302-312.	0.4	19